Suen T C, Goss P E
Breast Cancer Prevention Program, The Toronto Hospital, Oncology Research Laboratories, Toronto, Ontario, M5G 2M9, Canada.
J Biol Chem. 2000 Mar 3;275(9):6600-7. doi: 10.1074/jbc.275.9.6600.
The proto-oncogene neu (HER2 or c-erbB2) is overexpressed with or without gene amplification in 20-30% of breast cancers. In patients, neu amplification or overexpression in breast and ovarian cancer correlates with poor prognosis and tumor resistance to chemotherapy. neu-induced transformation can be reversed by the suppression of neu gene transcription. To further understand how neu gene transcription is regulated and to identify a possible transcriptional repressor(s) of neu, we identified a negative regulatory element known previously to be located within a 1-kilobase (kb) DNA fragment of an unknown sequence, upstream of the proximal neu gene promoter. One of several DNA fragments subcloned from this region suppressed transcriptional activity of the proximal neu gene promoter. Sequencing of the 1-kb fragment confirmed the location of the repressor element to be between an AluI and a RsaI sites, around 1.4 kb upstream to the translation start site. Various deletions were introduced into the AluI-RsaI fragment and subcloned into both the native neu promoter and a heterologous thymidine kinase promoter. Subsequent transfections and reporter gene assays in cell lines of various tissues of origin confirmed and narrowed the repressor activity to a 120-base pair NlaIV-MslI fragment located between -1385 and -1266. Importantly, specific protein binding activity to this element could be detected with nuclear extracts isolated from these cell lines. In contrast, a 28-base pair MslI-RsaI fragment (-1265 to -1238), located immediately 3' of the putative repressor element, was found to form protein-DNA complexes with only nuclear extracts isolated from a colon carcinoma cell line. This specific protein binding activity correlated with a previously unknown transcriptional stimulatory activity only in this cell line.
原癌基因neu(HER2或c-erbB2)在20%-30%的乳腺癌中存在过表达,伴或不伴基因扩增。在患者中,乳腺癌和卵巢癌中的neu扩增或过表达与预后不良及肿瘤对化疗的耐药性相关。neu诱导的转化可通过抑制neu基因转录来逆转。为了进一步了解neu基因转录是如何被调控的,并鉴定可能的neu转录抑制因子,我们鉴定了一个负调控元件,该元件先前已知位于近端neu基因启动子上游一个未知序列的1千碱基(kb)DNA片段内。从该区域亚克隆的几个DNA片段之一抑制了近端neu基因启动子的转录活性。对1 kb片段的测序证实了抑制元件的位置在一个AluI和一个RsaI位点之间,位于翻译起始位点上游约1.4 kb处。将各种缺失引入AluI-RsaI片段,并亚克隆到天然neu启动子和异源胸苷激酶启动子中。随后在各种来源组织的细胞系中进行转染和报告基因检测,证实并将抑制活性缩小到位于-1385至-1266之间的一个120碱基对的NlaIV-MslI片段。重要的是,用从这些细胞系中分离的核提取物可以检测到与该元件的特异性蛋白结合活性。相比之下,位于假定抑制元件紧下游3'的一个28碱基对的MslI-RsaI片段(-1265至-1238),仅与从一个结肠癌细胞系中分离的核提取物形成蛋白质-DNA复合物。这种特异性蛋白结合活性仅在该细胞系中与一种先前未知的转录刺激活性相关。